Antibiotic prophylaxis in neutropenic patients: New evidence, practical decisions

Cancer

Volumn 107, Issue 8, 2006, Pages 1743-1751

  Leibovici, Leonard ^a,b   Paul, Mical ^a,b   Cullen, Michael ^c   Bucaneve, Giampaolo ^d   Gafter Gvili, Anat ^a,b   Fraser, Abigail ^a   Kern, Winfried V ^e  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^d POLICLINICO MONTELUCE   (Italy)

^e UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Antibiotic prophylaxis; Ciprofloxacin; Levofloxacin; Neutropenia

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; LEVOFLOXACIN; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACUTE LEUKEMIA; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIUM ISOLATE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CONFIDENCE INTERVAL; DRUG EFFICACY; DRUG USE; EVIDENCE BASED PRACTICE; FEVER; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; LYMPHOMA; MORTALITY; NEUTROPENIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; SOLID TUMOR;

ACUTE DISEASE; ANTIBIOTIC PROPHYLAXIS; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CIPROFLOXACIN; DECISION MAKING; DRUG RESISTANCE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; LEUKEMIA; LYMPHOMA; NEOPLASMS; NEUTROPENIA; OFLOXACIN;

EID: 33750042267     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22205     Document Type: Review

References (46)

1. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005;142:979-995.
2. Bucaneve G, Micozzi A, Menichetti F, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353:977-987.
3. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005;353:988-998.
4. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-751.
5. Brodsky AL, Minissale CJ, Melero MJ, Sanchez Avalos JC. [Prophylaxis with fluoroquinolones in patients with neutropenia]. Medicina (B Aires). 1993;53:401-407.
6. Karp JE, Merz WG, Hendricksen C, et al. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukaemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1987;106:1-7.
7. Lee DG, Choi SM, Choi JH, et al. Selective bowel decontamination for the prevention of infection in acute myelogenous leukaemia: a prospective randomized trial. Korean J Intern Med. 2002;17:38-44.
8. Moreau P, Milplied N, Richard P, Bulbois CE, Richet H, Harousseau JL. Prospective randomized study comparing prophylactic ciprofloxacin (C) and amoxicillin + clavulanic acid (A-CA) versus prophylactic vancomycin (V) versus non-prophylactic conventional empirical antimicrobial therapy in neutropenic patients. Bone Marrow Transplant. 1995;15:S129. Abstract.
9. Nenova IS, Ananostev NH, Goranov SE, Mateva NG, Haidushka IA. Fluoroquinolone prophylaxis for bacterial infections in neutropenic patients with hematologic malignancies. Folia Med (Plovdiv). 2001;43:40-55.
10. Ruiz I, Fuentes I, Capdevila JA, et al. Ofloxacin prophylaxis in preventing bacterial infection after autologous peripheral blood stem cell transplantation (A-PBSC). In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; 2001:447. Abstract L-781.
11. Sampi K, Maseki N, Hattori M. [A comparison of nystatin with norfloxacin for prevention of infection after consolidation therapy in patients with acute leukaemia or autologous bone marrow transplantation: a randomized study]. Gan To Kagaku Ryoho. 1992;19:823-826.
12. Talbot GH, Cassileth PA, Paradiso L, Correa-Coronas R, Bond L. Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukaemia. The Enoxacin Prophylaxis Study Group. Antimicrob Agents Chemother. 1993;37:474-482.
13. Thomas X, Troncy J, Belhabri A, et al. [Effectiveness of combined vancomycin and pefloxacine in gastrointestinal decontamination for preventing infections after chemotherapy-induced bone marrow aplasia. A randomized double-blind study]. Presse Med. 2000;29:1745-1751.
14. Tsutani H, Imamura S, Ueda T, et al. Prophylactic use of ofloxacin in granulocytopenic patients with hematological malignancies during post-remission chemotherapy. Intern Med. 1992;31:319-324.
15. Yamada T, Dan K, Nomura T. Prevention of bacterial and fungal infections in acute leukaemia patients: a new and potent combination of oral norfloxacin and amphotericin B. Intern Med. 1993;32:710-715.
16. Casali A, Verri C, Paoletti G, et al. Chemoprophylaxis of bacterial infections in granulocytopenic cancer patients using norfloxacin. Chemioterapia. 1988;7:327-329.
17. Lew MA, Kehoe K, Ritz J, et al. Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation. 1991;51:630-636.
18. Maiche AG, Muhonen T. Granulocyte colony-stimulating factor (G-CSF) with or without a quinolone in the prevention of infection in cancer patients. Eur J Cancer. 1993;29A:1403-1405.
19. Carlson JW, Fowler JM, Mitchell SK, Carson LF, Mayer AR, Copeland LJ. Chemoprophylaxis with ciprofloxacin in ovarian cancer patients receiving paclitaxel: a randomized trial. Gynecol Oncol. 1997;65:325-329.
20. Hartlapp JH. Antimicrobial prophylaxis in immunocompromised patients. Drugs. 1987;34(Suppl 1):131-133.
21. Schroeder M, Schadeck-Gressel C, Selbach J, Westerhausen M. Antibiotic prophylaxis with gyrase inhibitors during cytostatically induced granulocytopenias in patients with solid tumors: a double-blind prospective randomized study. Onkologie. 1992;15:476-479.
22. Tjan-Heijnen VC, Postmus PE, Ardizzoni A, et al. Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled Phase III study. Ann Oncol. 2001;12:1359-1368.
23. Kern WV Steib-Bauert M, de With K, et al. Fluoroquinolone consumption and resistance in haematology-oncology patients-ecological analysis in two university hospitals 1999-2002. J Antimicrob Chemother. 2005;55:57-60.
24. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med. 1994;330:1240-1241.
25. Kern WV, Andriof E, Oethinger M, Kern R Hacker J, Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother. 1994;38:681-687.
26. Baum HV Franz U, Geiss HK. Prevalence of ciprofloxacin-resistant Escherichia coli in hematologic-oncologic patients. Infection. 2000;28:278-281.
27. Razonable RR, Litzow MR, Khaliq Y, Piper KE, Rouse MS, Patel R. Bacteremia due to viridans group streptococci with diminished susceptibility to levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis. 2002;34:1469-1474.
28. Leibovici L, Shraga I, Andreassen S. How do you choose antibiotic treatment? BMJ. 1999;318:1614-1618.
29. National Cancer Institute. SEER Statistics. Available from URL: http://seer.cancer.gov/statfacts [accessed August 24, 2006].
30. Griebling TL. Urologic diseases in America project: trends in resource use for urinary tract infections in men. J Urol. 2005;173:1288-1294.
31. Griebling TL. Urologic diseases in America project: trends in resource use for urinary tract infections in women. J Urol. 2005;173:1281-1287.
32. Vidal L, Paul M, Ben Dor I, Soares-Weiser K, Leibovici L. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients: a systematic review and meta-analysis of randomized trials. J Antimicrob Chemother. 2004;54:29-37.
33. Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukaemia. Eur J Clin Microbiol Infect Dis. 2005;24:111-118.
34. Reuter S, Kern WV, Sigge A, et al. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis. 2005;40:1087-1093.
35. Martino R, Subira M, Altes A, et al. Effect of discontinuing prophylaxis with norfloxacin in patients with hematologic malignancies and severe neutropenia. A matched case-control study of the effect on infectious morbidity. Acta Haematol. 1998;99:206-211.
36. Delarive P, Baumgartner JD, Glauser MP, Cometta A. Evaluation de la prophylaxie antibiotique chez les patients neutropeniques avec hemopathie maligne. Schweiz Med Wochenschr. 2000;130:1837-1844.
37. Gomez L, Garau J, Estrada C, et al. Ciprofloxacin prophylaxis in patients with acute leukaemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli. Cancer. 2003;97:419-424.
38. Gracia Escudero A, Martin Gonzalez M, Gimenez Garrido F, et al. Estudio prospectivo y controlado, no aleatorizado de tres cohortes sobre la efectividad de dos pautas antibioticas, levofloxacino y contrimoxazol, en profilaxis antibacteriana de pacientes neutropenicos. Med Clin (Barcelona). 2003;120:321-325.
39. Prentice HG, Hann IM, Nazareth B, Paterson P, Bhamra A, Kibbler CC. Oral ciprofloxacin plus colistin: prophylaxis against bacterial infection in neutropenic patients. A strategy for the prevention of emergence of antimicrobial resistance. Br J Haematol. 2001;115:46-52.
40. Fadda G, Nicoletti G, Schito GC, Tempera G. Antimicrobial susceptibility patterns of contemporary pathogens from uncomplicated urinary tract infections isolated in a multicenter Italian survey: possible impact on guidelines. J Chemother. 2005;17:251-257.
41. Luzzaro F, Vigano EF, Fossati D, et al. Prevalence and drug susceptibility of pathogens causing bloodstream infections in northern Italy: a two-year study in 16 hospitals. Eur J Clin Microbiol Infect Dis. 2002;21:849-855.
42. Kuijper EJ, van den Berg RJ, Debast S, et al. Clostridium difficile ribotype 027, toxinotype III, the Netherlands. Emerg Infect Dis. 2006;12:827-830.
43. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254-1260.
44. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353:2442-2449.
45. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433-2441.
46. Weiss K. Poor infection control, not fluoroquinolones, likely to be primary cause of Clostridium difficile-associated diarrhea outbreaks in Quebec. Clin Infect Dis. 2006;42:725-727.